X

Vous n'êtes pas connecté

  - ZACKS.COM - All Stories - 02/Jul 13:39

Can Multi-Basin Assets Fuel Devon Energy's Long-Term Growth?

DVN's multi-basin strategy fuels resilient growth, capital flexibility and strong shareholder returns.

Articles similaires

Sorry! Image not available at this time

Can Strategic Hedging Strengthen Vistra's Earnings and Growth Outlook?

zacks.com - 25/Jun 15:36

VST's robust hedging strategy boosts earnings visibility and fuels long-term growth.

Sorry! Image not available at this time

Can Strategic Hedging Strengthen Vistra's Earnings and Growth Outlook?

zacks.com - 25/Jun 15:36

VST's robust hedging strategy boosts earnings visibility and fuels long-term growth.

Sorry! Image not available at this time

Is UUUU's HMS Diversification Strategy a Smart Long-Term Move?

zacks.com - 20/Jun 15:50

Energy Fuels shifts strategy from uranium, leaning on HMS assets like Toliara and Bahia.

Sorry! Image not available at this time

Can EMCOR's Data Center Expansion Fuel Long-Term Growth?

zacks.com - 30/Jun 13:39

EMCOR's $3.6 billion in data center projects, up 112%, signals strong momentum in AI and cloud infrastructure demand.

Sorry! Image not available at this time

Can EMCOR's Data Center Expansion Fuel Long-Term Growth?

zacks.com - 30/Jun 13:39

EMCOR's $3.6 billion in data center projects, up 112%, signals strong momentum in AI and cloud infrastructure demand.

Sorry! Image not available at this time

Can Float Fuel Berkshire's Long-Term Growth and Value Creation?

zacks.com - 23/Jun 16:20

Float's steady rise to $173B is powering BRK.B's long-term growth, despite EPS estimate cuts and a premium valuation.

Sorry! Image not available at this time

Can Float Fuel Berkshire's Long-Term Growth and Value Creation?

zacks.com - 23/Jun 16:20

Float's steady rise to $173B is powering BRK.B's long-term growth, despite EPS estimate cuts and a premium valuation.

Sorry! Image not available at this time

Pfizer's Strong Late-Stage Pipeline Can Drive Long-Term Growth

zacks.com - 01/Jul 13:35

PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.